JP2014519018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519018A5 JP2014519018A5 JP2014508608A JP2014508608A JP2014519018A5 JP 2014519018 A5 JP2014519018 A5 JP 2014519018A5 JP 2014508608 A JP2014508608 A JP 2014508608A JP 2014508608 A JP2014508608 A JP 2014508608A JP 2014519018 A5 JP2014519018 A5 JP 2014519018A5
- Authority
- JP
- Japan
- Prior art keywords
- difficile
- lactoferrin
- stool sample
- patient
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 36
- 108010063045 Lactoferrin Proteins 0.000 claims 24
- 102100032241 Lactotransferrin Human genes 0.000 claims 24
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 24
- 229940078795 lactoferrin Drugs 0.000 claims 24
- 235000021242 lactoferrin Nutrition 0.000 claims 24
- 201000010099 disease Diseases 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims 15
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims 15
- 239000000090 biomarker Substances 0.000 claims 11
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 claims 2
- 108010074051 C-Reactive Protein Proteins 0.000 claims 2
- 102100032752 C-reactive protein Human genes 0.000 claims 2
- 102000016901 Glutamate dehydrogenase Human genes 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 2
- 101710182223 Toxin B Proteins 0.000 claims 2
- 101710182532 Toxin a Proteins 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 238000004820 blood count Methods 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 101150032575 tcdA gene Proteins 0.000 claims 1
- 101150089436 tcdB gene Proteins 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480616P | 2011-04-29 | 2011-04-29 | |
| US61/480,616 | 2011-04-29 | ||
| US13/457,064 US20120276060A1 (en) | 2011-04-29 | 2012-04-26 | Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease |
| US13/457,049 | 2012-04-26 | ||
| US13/457,064 | 2012-04-26 | ||
| US13/457,049 US20120276059A1 (en) | 2011-04-29 | 2012-04-26 | Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease |
| PCT/US2012/035495 WO2012149351A1 (en) | 2011-04-29 | 2012-04-27 | Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519018A JP2014519018A (ja) | 2014-08-07 |
| JP2014519018A5 true JP2014519018A5 (enExample) | 2015-06-18 |
| JP6077524B2 JP6077524B2 (ja) | 2017-02-08 |
Family
ID=47068058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508608A Active JP6077524B2 (ja) | 2011-04-29 | 2012-04-27 | クロストリジウム・ディフィシル疾患を有する患者において疾患の重症度を決定するための、および感染を監視するためのバイオマーカーとしての糞便中のラクトフェリン |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20120276059A1 (enExample) |
| EP (1) | EP2705154A4 (enExample) |
| JP (1) | JP6077524B2 (enExample) |
| CA (1) | CA2834400A1 (enExample) |
| WO (1) | WO2012149351A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4032586T3 (fi) | 2010-02-01 | 2025-11-25 | Ferring Microbiome Inc | Bakteeriterapia clostridium difficile -koliittiin |
| US20120276059A1 (en) | 2011-04-29 | 2012-11-01 | Techlab, Inc. | Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease |
| US10295535B2 (en) * | 2011-04-29 | 2019-05-21 | Techlab, Inc. | Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with clostridium difficile disease and differentiating carrier state from active disease |
| US9133527B2 (en) | 2012-05-11 | 2015-09-15 | Techlab, Inc. | Cell wall protein CwpV (CD0514) as a diagnostic marker for Clostridium difficile ribotype 027 |
| WO2014197562A1 (en) | 2013-06-05 | 2014-12-11 | Rebiotix, Inc. | Microbiota restoration therapy (mrt), compositions and methods of manufacture |
| US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
| US10513552B2 (en) | 2014-06-20 | 2019-12-24 | Immunimed Inc. | Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease |
| EP2957570B1 (en) * | 2014-06-20 | 2019-04-17 | Immunimed Inc. | Polyclonal antibodies against clostridium difficile and uses thereof |
| JP6616431B2 (ja) | 2015-06-09 | 2019-12-04 | レビオティクス インコーポレイテッド | マイクロバイオータ回復治療（ｍｒｔ）組成物の製造方法 |
| US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
| EA034885B1 (ru) * | 2015-07-03 | 2020-04-02 | Астеллас Фарма Юэроп Лтд. | Новая схема лечения тиакумициновым соединением |
| WO2017100420A1 (en) * | 2015-12-08 | 2017-06-15 | Mayo Foundation For Medical Education And Research | Biomarkers for predicting clostridium difficile infection treatment outcome |
| CN109682979A (zh) * | 2019-01-30 | 2019-04-26 | 珠海市银科医学工程股份有限公司 | 一种钙卫蛋白联合乳铁蛋白抗原检测试纸条及其制备方法 |
| US12322493B2 (en) | 2020-12-29 | 2025-06-03 | Kpn Innovations, Llc. | Systems and methods for generating a lifestyle-based disease prevention plan |
| US11139063B1 (en) | 2020-12-29 | 2021-10-05 | Kpn Innovations, Llc. | Systems and methods for generating a microbiome balance plan for prevention of bacterial infection |
| US12322491B2 (en) | 2021-03-01 | 2025-06-03 | Kpn Innovations, Llc. | System and method for generating a geographically linked nourishment program |
| WO2022206585A1 (zh) * | 2021-03-29 | 2022-10-06 | 广州市妇女儿童医疗中心 | 诊断先天性巨结肠的抗体标志物及其应用 |
| CN114252596A (zh) * | 2021-12-01 | 2022-03-29 | 珠海科域生物工程股份有限公司 | 一种粪便乳铁蛋白检测试剂盒及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965375A (en) | 1997-04-04 | 1999-10-12 | Biosite Diagnostics | Diagnostic tests and kits for Clostridium difficile |
| JP2000155121A (ja) * | 1998-11-18 | 2000-06-06 | Nitto Denko Corp | 免疫学的検査法 |
| AU2002902A (en) | 2000-11-14 | 2002-05-27 | Techlab Inc | Method for differentiating irritable bowel syndrome from inflammatory bowel disease (ibd) and for monitoring persons with ibd using total endogenous lactoferrinas a marker |
| AU2005309443B2 (en) | 2004-11-24 | 2011-03-03 | Techlab, Inc. | Device and method for detection of analytes |
| CA2714720A1 (en) | 2008-02-28 | 2009-09-03 | 3M Innovative Properties Company | Antibodies to clostridium difficile spores and uses thereof |
| US20120276059A1 (en) | 2011-04-29 | 2012-11-01 | Techlab, Inc. | Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease |
-
2012
- 2012-04-26 US US13/457,049 patent/US20120276059A1/en not_active Abandoned
- 2012-04-26 US US13/457,064 patent/US20120276060A1/en not_active Abandoned
- 2012-04-27 CA CA2834400A patent/CA2834400A1/en not_active Abandoned
- 2012-04-27 JP JP2014508608A patent/JP6077524B2/ja active Active
- 2012-04-27 EP EP12777788.6A patent/EP2705154A4/en not_active Ceased
- 2012-04-27 WO PCT/US2012/035495 patent/WO2012149351A1/en not_active Ceased
-
2014
- 2014-04-10 US US14/249,814 patent/US10295536B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519018A5 (enExample) | ||
| Natividad et al. | Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice | |
| Verhaar et al. | Gut microbiota composition is related to AD pathology | |
| Giannoudaki et al. | Interleukin-36 cytokines alter the intestinal microbiome and can protect against obesity and metabolic dysfunction | |
| Hu et al. | The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies | |
| Bervoets et al. | Differences in gut microbiota composition between obese and lean children: a cross-sectional study | |
| Su et al. | Fecal microbiota transplantation and replenishment of short-chain fatty acids protect against chronic cerebral hypoperfusion-induced colonic dysfunction by regulating gut microbiota, differentiation of Th17 cells, and mitochondrial energy metabolism | |
| Lin et al. | Kidney injury molecule-1 expression in IgA nephropathy and its correlation with hypoxia and tubulointerstitial inflammation | |
| US20120276059A1 (en) | Fecal lactoferrin as a biomarker for determining disease severity and for monitoring infection in patients with clostridium difficile disease | |
| Li et al. | Bacteroides ovatus-mediated CD27− MAIT cell activation is associated with obesity-related T2D progression | |
| Cho et al. | Associations of high‐dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial | |
| Srivastava et al. | Associations between IL‐1 RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India | |
| Kaido et al. | Perioperative changes of procalcitonin levels in patients undergoing liver transplantation | |
| US20200308644A1 (en) | Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease | |
| Fluitman et al. | Gut microbial characteristics in poor appetite and undernutrition: a cohort of older adults and microbiota transfer in germ‐free mice | |
| Gagliardi et al. | Malnutrition, infection and arteriovenous fistula failure: is there a link? | |
| JP6779200B2 (ja) | 川崎病の診断及び治療 | |
| CA2871613C (en) | Clostridium difficile dehydrogenase and toxin as a biomarker | |
| Ramendra et al. | Airway pepsinogen A4 identifies lung transplant recipients with microaspiration and predicts chronic lung allograft dysfunction | |
| Zhang et al. | Decreased preoperative urinary uromodulin as a predictor of acute kidney injury and perioperative kidney dysfunction in patients undergoing cardiac surgery: A prospective cohort study | |
| Liu et al. | Activation of CD3+ TIM3+ T cells contributes to excessive inflammatory response during glucocorticoid treatment | |
| CN107557490A (zh) | Cxcl13作为生物标志物在诊断试剂中的用途 | |
| US20210247394A1 (en) | Isolated bacterial strain for inducing proliferation or accumulation of regulatory t-cells | |
| EP2971061A1 (en) | Method for identifying a bacterial infection | |
| RU2340902C1 (ru) | Способ диагностики тяжести воспалительного процесса при бактериальных гнойных менингитах у детей |